1027345-19-2

Upstream product

• 4255-62-3 4,4-dimethylcyclohexane-1-one 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 50388-51-7 methyl 5,5-dimethyl-2-oxo-cyclohexanecarboxylate 

Downstream Products

• 1027345-20-5 methyl 2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enecarboxylate 
• 1027345-21-6 (4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 
• 1027345-22-7 6-(bromomethyl)-4'-chloro-4,4-dimethyl-2,3,4,5-tetrahydro-1,1'-biphenyl 
• 1027345-23-8 7-(4-((4'-chloro-(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)quinazolin-4-ol 
• 1027345-24-9 4-chloro-7-(4-((4'-chloro-(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)quinazoline 
• 1027345-26-1 4-chloro-7-{4-[(2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl]piperazin-1-yl}quinazoline 
• 1027345-25-0 7-[4-(4'-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl]-quinazolin-4-ol 
• 1197199-73-7 N-(7-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1-yl)quinazolin-4-yl)-3-nitro-4-(2-(phenylthio)ethylamino)benzenesulfonamide 

Relevant academic research and scientific papers

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti apoptotic protein family member.

ARYLSULFONAMIDE COMPOUNDS

The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mim